Identity
Avobenzone — INCI name butyl methoxydibenzoylmethane, often abbreviated BMDBM and sold under trade names including Parsol 1789 — is an oil-soluble dibenzoyl methane derivative used as a topical long-wave UVA filter.
Its role in the market is structural rather than merely popular: in US commercial sunscreens, only avobenzone and zinc oxide are regularly used for long-wave UVA protection. That scarcity is a consequence of the American approval process rather than of chemistry — the EU and Australia have had access to additional photostable UVA filters for years.
⚠️ Not to be confused with oxybenzone (benzophenone-3), a different filter with a different profile and a different regulatory history. The similar names are the most common source of confusion in this category.
How it works, and why it stops working
Avobenzone absorbs UVA radiation in its enol tautomeric form, which is the form that gives it its exceptionally broad UVA absorption curve.
The problem is that UV exposure drives keto-enol tautomerism. Ultraviolet light shifts the equilibrium from the enol form toward the diketo form — and the diketo form absorbs in the UVC range, not UVA. The filter is still present in the product; it has simply stopped doing the job it was included for. Reported effectiveness loss without stabilisation is on the order of 30-60 minutes of sun exposure.
Two consequences follow, and they are different in kind. The first is loss of protection. The second is that degradation generates free radicals and cytotoxic benzophenone-like byproducts — meaning a filter included to prevent UV-driven oxidative damage can contribute to it as it breaks down.
Stabilisation: the thing that actually determines whether it works
Because of this, avobenzone is essentially never used alone in a competent formulation, and three decades of formulation research have gone into stabilising it.
Octocrylene is the most effective and most common route. It absorbs the UV energy that would otherwise drive avobenzone's degradation, and it happens to be an excellent solubiliser for it — avobenzone dissolves in octocrylene at around 13% at ambient temperature, which lets formulators reduce the total oil content and improve skin feel. It also contributes UVB absorption in its own right. In testing, octocrylene alone retained roughly 92% of the UVA protection factor.
Other routes: excited-state quenchers such as diethylhexyl 2,6-naphthalate and ethylhexyl methoxycrylene; the broad-spectrum photostable filters bemotrizinol (Tinosorb S) and bisoctrizole (Tinosorb M); and encapsulation, which shields the molecule from light and oxygen. Well-designed systems reach 90-100% photostability even after irradiation at 25 MED.
Here is the practical problem for a consumer: none of this is visible on the label. An ingredient list shows that octocrylene is present; it does not show the ratio, the formulation architecture, or whether photostability was actually achieved and tested. Two products listing the same two filters can behave completely differently — which is the same formulation-not-percentage principle that governs actives generally.
And for the US market specifically, the best stabilising filters were long unavailable — much of why octocrylene became the workhorse there. That changed in June 2026, when the FDA approved bemotrizinol (Tinosorb S) as GRASE up to 6% (Final Administrative Order OTC000039, added to the OTC monograph M020; Federal Register 10 June 2026, effective 9 August 2026) — the first new US monograph sunscreen active since the late 1990s. Bisoctrizole (Tinosorb M) remains unapproved.
Reading the evidence honestly
On protection: avobenzone's UVA coverage is genuinely excellent, and in the US it is close to indispensable — there is no organic alternative for long UVA. That is a real strength, conditional on formulation.
On absorption: the FDA's 2020 JAMA study is the most-cited and most-misread paper in sun care. It applied sunscreen to 75% of the body four times daily for four days — a maximal-use protocol, not typical use — and found avobenzone and three other filters exceeded 0.5 ng/mL in plasma. The 0.5 ng/mL threshold is a regulatory trigger for additional testing, not a danger line. The study demonstrated that these filters are absorbed. It did not demonstrate that absorption causes harm, and its authors did not claim it did.
On toxicity: a comprehensive 2025 toxicology review concluded avobenzone shows minimal toxicity, no evidence of carcinogenicity, and no effects on estrogen, androgen or thyroid systems at real-world exposure levels, alongside a long history of use.
On regulatory status: Category III means the requested safety data were not submitted, not that the filter failed assessment. This distinction is routinely erased in marketing that contrasts "safe mineral" with "chemical" filters.
The honest summary: a highly effective UVA filter with a serious inherent instability that formulation can solve but the label cannot demonstrate, absorbed into the body at levels that triggered regulatory attention, with no demonstrated harm to date and incomplete data by the FDA's own standard. Grade B reflects that combination — not a verdict of risk, and not a clean bill of health either.